The DOI matches its Crossref record; 217 of the 218 references it cites were found in a registry or an index.
mRNA vaccines — a new era in vaccinology
Open accessAbstract
mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. However, their application has until recently been restricted by the instability and inefficient in vivo delivery of mRNA. Recent technological advances have now largely overcome these issues, and multiple mRNA vaccine platforms against infectious diseases and several types of cancer have demonstrated encouraging results in both animal models and humans. This Review provides a detailed overview of mRNA vaccines and considers future directions and challenges in advancing this promising vaccine platform to widespread therapeutic use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“mRNA production and lipid nanoparticle formulation are fast and highly scalable, which renders this technology suitable for the rapid development and supply of vaccines during pandemic scenarios 11,12 .”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“samRNA vaccines can induce potent immune responses at lower doses due to their ability to amplify antigen production within the body, potentially reducing the risk of adverse reactions6,44.”
From An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial (2024) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, we focused on ψ and m1ψ, since these substitutions for U have been widely adopted for mRNA therapeutics and vaccines due to improved in-cell translation and to better control of innate immune responses2,3,8,67 through avoidance of recognition by cellular toll-like receptors (TLR7 and TLR8)68, RIG‑I, and PKR69–71.”
From Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics (2022) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The technique can be easily scaled requiring minimum platform changes during mRNA formulation and production (Pardi et al. 2018).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Pardi et al. 2018
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“which is widely believed to be critical to the recent success of mRNA vaccines1,2,10,37,38”
From Algorithm for optimized mRNA design improves stability and immunogenicity (2023) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“The mRNA also does not interact with the genome and only the parts directly required for the encoded protein expression are present in this basic genetic construct (Pardi et al. 2018).”
From Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency (2022) · cites this paper as Pardi et al. 2018
In the citing paper
“Both BNT162b2 and mRNA-1273, as well as the adenoviral-vectored vaccine ChAdOx1 nCoV-19, have been shown to induce type I interferon, thus potentially inducing pathogen-agnostic protection75–77.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [75]
In the citing paper
“Non-replicating mRNA vaccines deliver exclusively genetic information coding for the target antigen, thus containing the 5′-cap, 5′ untranslated region (UTR), 3′ UTR, and 3′-poly(A) tail regions.108”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [108]
In the citing paper
“Furthermore, the upscaling of cell-free vaccine production is relatively straightforward, thereby providing a cutting-edge tool for rapid response in epidemics and pandemics.4, 5, 6, 7”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [5]
In the citing paper
“Unlike some viral vaccines, mRNA does not integrate into the genome, obviating concerns about insertional mutagenesis5.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [5]
In the citing paper
“The use of modified nucleosides, particularly modified uridine, prevents recognition by pattern recognition receptors, enabling sufficient levels of translation to produce prophylactic amounts of protein5.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [5]
In the citing paper
“although it has been employed for various therapeutic targets, its use as a source of antigen in vaccination approaches is by far the most popular [2]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [2]
In the citing paper
“mRNA has shown therapeutic potential in a range of applications, including viral vaccines, protein replacement therapies, cancer immunotherapies, cellular reprogramming and genome editing2,4,7–17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“mRNA normally contains five structural elements, that is, a 5′ cap, a 3′ poly(A) tail, a protein-coding sequence and 5′ and 3′ untranslated regions (UTRs)2,4,7,13.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“mRNA is susceptible to degradation and, thus, formulation buffers should be free of any ribonuclease contaminations2,4.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“These elements can be engineered to improve the stability and translational efficiency of mRNA2,4,7,13.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“Chromatographic purification can remove double-stranded RNA, an analogue of viral genome, in IVT mRNA preparations, diminishing immune activation and increasing translational efficiency2,4,7,183.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“Chemical modifications of specific IVT mRNA nucleotides, such as pseudouridine (ψ) and N1-methylpseudouridine (m1ψ), can reduce innate immune sensing of exogenous mRNA translation2,4,7,182.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“Many other lipid nanoparticle–mRNA formulations are in clinical trials for the treatment of infectious diseases, cancer and genetic disorders2,4,8,12–14 (Tables 1,2).”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“These features make lipid nanoparticle–mRNA formulations a flexible and on-demand vaccine platform to rapidly respond to emerging infectious pathogens4,15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“To address these concerns, the engineering of mRNA molecules (Box 1) and the design of lipid nanoparticles have been optimized2,4,7–17, which has contributed to the rapid development and clinical assessment15,17 of the two COVID-19 mRNA vaccines, mRNA-1273 (NCT04470427)19,20 and BNT162b2 (NCT04368728)21.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“Since then, lipid nanoparticle–mRNA formulations have emerged as a potent alternative to conventional vaccine platforms, owing to their unique features4,15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“Moreover, mRNA-based cellular reprogramming, tissue regeneration and genome editing have shown therapeutic potential in preclinical studies2,4,8,12–14.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“First, mRNA is a non-infective and non-integrating agent with the ability to encode a broad range of antigens4,15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“Finally, GMP-grade lipid nanoparticle-mRNA vaccines can be manufactured for specific antigens in a short period of time, compared with other vaccine platforms, such as recombinant proteins and inactivated vaccines2,4,15,17.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“Neoantigens are often different between individual patients, allowing the development of personalized vaccines4,11.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“Neoantigens, generated by somatic mutations in cancer cells, are usually tumour-specific and have high immunogenicity4,11.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“The sequences of these elements regulate translation initiation, translation termination and post-transcriptional modification of mRNA molecules2,4.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“To achieve effective translation, mRNA requires five structural elements, including the 5′ cap, 3′ poly(A) tail, protein-coding sequence and 5′ and 3′ untranslated regions (UTRs)2,4.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [4]
In the citing paper
“the application of RNA vaccines has been limited by their lack of stability and requirement for a cold chain”
From A guide to vaccinology: from basic principles to new developments (2021) · cites this paper as [131]
In the citing paper
“RNA vaccines, for example, have exhibited encouraging results in both infection therapy and cancer immunotherapy.[6, 7, 11–15]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [12]
In the citing paper
“mRNA functions as the bridge between DNA and proteins in eukaryotic cells.[8, 12, 119]”
From RNA delivery biomaterials for the treatment of genetic and rare diseases (2019) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
An immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Self-citationPersonalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Self-citationSystemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
Johnston, R. J., Poholek, A. C., DiToro, D., Yusuf, I., Eto, D., Barnett, B., Dent, A. L., Craft, J., & Crotty, S. (2009) · Science · doi:10.1126/science.1175870 · Cited by 1,626
Bcl6 mediates the development of T follicular helper cells
Nurieva, R. I., Chung, Y., Martinez, G. J., Yang, X. O., Tanaka, S., Matskevitch, T. D., Wang, Y.-H., & Dong, C. (2009) · Science · doi:10.1126/science.1176676 · Cited by 1,506
Flagged first, then by citations
1 of the 218 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 701–800 of 1,011
Immunosenescence: How Aging Increases Susceptibility to Bacterial Infections and Virulence Factors
Theodorakis, N., Feretzakis, G., Hitas, C., Kreouzi, M., Kalantzi, S., Spyridaki, A., Kollia, Z., Verykios, V. S., & Nikolaou, M. (2024) · Microorganisms · doi:10.3390/microorganisms12102052 · Cited by 68
Innovations in structure-based antigen design and immune monitoring for next generation vaccines
Ward, A. B., & Wilson, I. A. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.03.013 · Cited by 62
CodonBERT large language model for mRNA vaccinesPreprint
Li, S., Moayedpour, S., Li, R., Bailey, M., Riahi, S., Kogler-Anele, L., Miladi, M., Miner, J. C., Pertuy, F., Zheng, D., et al. (2024) · Genome Research · doi:10.1101/gr.278870.123 · Cited by 66
Linares-Fernández, S., Moreno, J., Lambert, E., Mercier-Gouy, P., Vachez, L., Verrier, B., & Exposito, J.-Y. (2021) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2021.10.007 · Cited by 62
mRNA vaccines: A matter of delivery
Cao, Y., & Gao, G. F. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100746 · Cited by 61
COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform
Ashraf, M. U., Kim, Y., Kumar, S., Seo, D., Ashraf, M., & Bae, Y. (2021) · Vaccines · doi:10.3390/vaccines9020171 · Cited by 62
Immunopeptidomics for next-generation bacterial vaccine development
Mayer, R. L., & Impens, F. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.04.010 · Cited by 60
Improving aptamer performance with nucleic acid mimics: de novo and post-SELEX approaches
Oliveira, R., Pinho, E., Sousa, A. L., DeStefano, J. J., Azevedo, N. F., & Almeida, C. (2021) · Trends in biotechnology · doi:10.1016/j.tibtech.2021.09.011 · Cited by 61
New diagnosis of multiple sclerosis in the setting of mRNA COVID-19 vaccine exposure
Toljan, K., Amin, M., Kunchok, A. C., & Ontaneda, D. (2021) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2021.577785 · Cited by 61
mRNA-Based Therapeutics in Cancer Treatment
Sun, H., Zhang, Y., Wang, G., Yang, W., & Xu, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020622 · Cited by 65
Bernard, M., Bazin, E., Petiot, N., Lemdani, K., Commandeur, S., Verdelet, C., Margot, S., Perkov, V., Ripoll, M., Garinot, M., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.004 · Cited by 63
Qiu, K., Duan, X., Mao, M., Song, Y., Rao, Y., Cheng, D., Feng, L., Shao, X., Jiang, C., Huang, H., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00733-8 · Cited by 63
Shaw, C. A., Essink, B. J., Harper, C., Mithani, R., Kapoor, A., Dhar, R., Wilson, L. A., Guo, R., Panozzo, C. A., Wilson, E. M. P., et al. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae081 · Cited by 62
Influence of ionizable lipid tail length on lipid nanoparticle delivery of mRNA of varying length
Mrksich, K., Padilla, M. S., Joseph, R. A., Han, E. L., Kim, D., Palanki, R., Xu, J., & Mitchell, M. J. (2024) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.37705 · Cited by 67
Ongun, M., Lokras, A. G., Baghel, S. S., Shi, Z., Schmidt, S., Franzyk, H., Rades, T., Sebastiani, F., Thakur, A., & Foged, C. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114266 · Cited by 63
mRNA therapies: Pioneering a new era in rare genetic disease treatment
Shen, G., Liu, J., Yang, H., Xie, N., & Yang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.03.056 · Cited by 62
Advances and prospects of RNA delivery nanoplatforms for cancer therapy
Attia, M. S., Kijanka, G. S., Nguyen, N., Zhang, J., & An, H. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.09.009 · Cited by 64
Therapeutic mRNA delivery to leukocytes
Granot-Matok, Y., Kon, E., Dammes, N., Mechtinger, G., & Peer, D. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.032 · Cited by 64
Wang, F., Xiao, W., Elbahnasawy, M. A., Bao, X., Zheng, Q., Gong, L., Zhou, Y., Yang, S., Fang, A., Farag, M. M. S., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00980 · Cited by 59
Global efforts on vaccines for COVID-19: Since, sooner or later, we all will catch the coronavirus
Mukherjee, R. (2020) · Journal of Biosciences · doi:10.1007/s12038-020-00040-7 · Cited by 62
Reasons for success and lessons learnt from nanoscale vaccines against COVID-19
Kisby, T., Yılmazer, A., & Kostarelos, K. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00946-9 · Cited by 62
Recent Advances in the Noninvasive Delivery of mRNA
Qin, M., Du, G., & Sun, X. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00493 · Cited by 62
Antigenic characterization of influenza and SARS-CoV-2 viruses
Wang, Y., Tang, C. Y., & Wan, X. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03806-6 · Cited by 62
A Narrative Review of COVID-19 Vaccines
Eroglu, B., Nuwarda, R. F., Ramzan, I. M., & Kayser, V. (2021) · Vaccines · doi:10.3390/vaccines10010062 · Cited by 59
Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine
Kramer, K. J., Wilfong, E. M., Voss, K., Barone, S. M., Shiakolas, A. R., Raju, N., Roe, C. E., Suryadevara, N., Walker, L. M., Wall, S. C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31142-5 · Cited by 59
Nanomaterials‐Mediated Co‐Stimulation of Toll‐Like Receptors and CD40 for Antitumor Immunity
Yan, J., Zhang, Y., Du, S., Hou, X., Li, W., Zeng, C., Zhang, C., Cheng, J. K. J., Deng, B., McComb, D. W., et al. (2022) · Advanced Materials · doi:10.1002/adma.202207486 · Cited by 61
Extracellular vesicles as next generation immunotherapeutics
Greening, D. W., Xu, R., Ale, A., Hagemeyer, C. E., & Chen, W. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.02.002 · Cited by 61
Delivery technologies for women’s health applications
Swingle, K. L., Ricciardi, A. S., Peranteau, W. H., & Mitchell, M. J. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00040-w · Cited by 64
Feng, X., Shi, Y., Zhang, Y., Lei, F., Ren, R., & Tang, X. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s446919 · Cited by 67
Patra, P., Upadhyay, T. K., Alshammari, N. I., Saeed, M., & Kesari, K. K. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00984 · Cited by 63
Nelson, C. S., Jenks, J. A., Pardi, N., Goodwin, M. L., Roark, H. K., Edwards, W., McLellan, J. S., Pollara, J., Weissman, D., & Permar, S. R. (2020) · Journal of Virology · doi:10.1128/jvi.00186-20 · Cited by 58
Self-citationInvestigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines
Anderluzzi, G., Lou, G., Gallorini, S., Brazzoli, M., Johnson, R., O’Hagan, D. T., Baudner, B. C., & Perrie, Y. (2020) · Vaccines · doi:10.3390/vaccines8020212 · Cited by 57
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines
Wei, J., & Hui, A.-M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102405 · Cited by 57
Zhu, Y., Li, J., & Pang, Z. (2020) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2020.06.001 · Cited by 59
Disease control tools to secure animal and public health in a densely populated world
Charlier, J., Barkema, H. W., Becher, P., Benedictis, P. D., Hansson, I., Hennig‐Pauka, I., Ragione, R. M. L., Larsen, L. E., Madoroba, E., Maes, D. G. D., et al. (2022) · The Lancet Planetary Health · doi:10.1016/s2542-5196(22)00147-4 · Cited by 59
Karunakaran, B., Gupta, R., Patel, P., Salave, S., Sharma, A. K., Desai, D. N., Benival, D. M., & Kommineni, N. (2023) · Vaccines · doi:10.3390/vaccines11030661 · Cited by 64
The mRNA-LNP vaccines – the good, the bad and the ugly?
Igyártó, B. Z., & Qin, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1336906 · Cited by 61
Principles of lipid nanoparticle design for mRNA delivery
Zhang, Y., Zhang, X., Gao, Y., & Liu, S. (2024) · BMEMat · doi:10.1002/bmm2.12116 · Cited by 62
Intracellular Routing and Recognition of Lipid-Based mRNA Nanoparticles
Delehedde, C., Even, L., Midoux, P., Pichon, C., & Perche, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13070945 · Cited by 60
Guevara, M. L., Jilesen, Z., Stojdl, D., & Persano, S. (2019) · ACS Omega · doi:10.1021/acsomega.9b00489 · Cited by 58
mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates
Corbett, K. S., Werner, A. P., Connell, S. O., Gagné, M., Lai, L., Moliva, J. I., Flynn, B. J., Choi, A., Koch, M., Foulds, K. E., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-01021-0 · Cited by 57
Zhang, R., Jing, W., Chen, C., Zhang, S., Abdalla, M., Sun, P., Wang, G., You, W., Yang, Z., Zhang, J., et al. (2022) · Advanced Materials · doi:10.1002/adma.202107506 · Cited by 58
Li, C. Y., Liang, Z., Hu, Y., Zhang, H., Setiasabda, K. D., Li, J., Ma, S., Xia, X., & Kuang, Y. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.10.003 · Cited by 58
Gu, Y., Yang, H. J., He, C., Zhao, T., Lu, R., Liu, J., Mo, X., Wen, F., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01479-4 · Cited by 61
Inhalable dry powder product (DPP) of mRNA lipid nanoparticles (LNPs) for pulmonary delivery
Sarode, A., Patel, P., Vargas‐Montoya, N., Allawzi, A. M., Zhilin-Roth, A., Karmakar, S., Boeglin, L., Deng, H., Karve, S., & DeRosa, F. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01402-y · Cited by 64
Targeting Tumor Heterogeneity with Neoantigen-Based Cancer Vaccines
Pounraj, S., Chen, S., Ma, L., Mazzieri, R., Dolcetti, R., & Rehm, B. H. A. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-2042 · Cited by 61
Li, J., Miller, L. C., & Sang, Y. (2024) · Vaccines · doi:10.3390/vaccines12060606 · Cited by 62
RNA vaccines for cancer: Principles to practice
Guasp, P., Reiche, C., Sethna, Z. M., & Balachandran, V. P. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.05.005 · Cited by 64
Parvin, N., Joo, S. W., & Mandal, T. K. (2024) · Biomolecules · doi:10.3390/biom14081036 · Cited by 65
Emerging Prospects for Nanoparticle‐Enabled Cancer Immunotherapy
Buabeid, M. A., Arafa, E. A., & Murtaza, G. (2020) · Journal of Immunology Research · doi:10.1155/2020/9624532 · Cited by 61
Nanomedicine strategies to target coronavirus
Heinrich, M. A., Martina, B. E. E., & Prakash, J. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100961 · Cited by 60
Schmidt, M. J., Gupta, A. K., Bednarski, C., Gehrig-Giannini, S., Richter, F. M., Pitzler, C., Gamalinda, M., Galonska, C., Takeuchi, R., Wang, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24454-5 · Cited by 58
mRNA, a Revolution in Biomedicine
Baptista, B., Carapito, R., Laroui, N., Pichon, C., & de Sousa, F. P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13122090 · Cited by 61
Vaccination and immunotherapies in neuroimmunological diseases
Winkelmann, A., Loebermann, M., Barnett, M. H., Hartung, H., & Zettl, U. K. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00646-5 · Cited by 64
COVID-19 and pregnancy: clinical outcomes; mechanisms, and vaccine efficacy
Kumar, D., Verma, S., & Mysorekar, I. U. (2022) · Translational research · doi:10.1016/j.trsl.2022.08.007 · Cited by 59
Monkeypox virus: An emerging epidemic
Aljabali, A. A. A., Obeid, M. A., Nusair, M. B., Hmedat, A., & Tambuwala, M. M. (2022) · Microbial Pathogenesis · doi:10.1016/j.micpath.2022.105794 · Cited by 60
Chien, Y., Hsiao, Y., Chou, S., Lin, T.-Y., Yarmishyn, A. A., Lai, W., Lee, M., Lin, Y., Lin, T.-W., Hwang, D., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01717-x · Cited by 59
Advances of mRNA vaccine in tumor: a maze of opportunities and challenges
Yuan, Y., Gao, F., Chang, Y., Zhao, Q., & He, X. (2023) · Biomarker Research · doi:10.1186/s40364-023-00449-w · Cited by 60
Development and applications of mRNA treatment based on lipid nanoparticles
Wang, Z., Ma, W., Fu, X., Qi, Y., Zhao, Y., & Zhang, S. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108130 · Cited by 57
Combination of micelles and liposomes as a promising drug delivery system: a review
Qian, J., Guo, Y., Xu, Y., Wang, X., Chen, J., & Wu, X. (2023) · Drug Delivery and Translational Research · doi:10.1007/s13346-023-01368-x · Cited by 59
Tockary, T. A., Abbasi, S., Matsui-Masai, M., Hayashi, A., Yoshinaga, N., Boonstra, E., Wang, Z., Fukushima, S., Kataoka, K., & Uchida, S. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2214320120 · Cited by 56
Ren, Y., Lin, L., Abdallah, M., Zhu, X., Liu, H., Fabb, S. A., Payne, T. J., Pouton, C. W., Johnston, A. P. R., & Trevaskis, N. L. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113945 · Cited by 64
Al-Azzani, H., Vithran, D. T. A., Aliouat, H., Zhou, W., & Mao, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1675682 · Cited by 66
Kawaguchi, D., Kodama, A., Abe, N., Takebuchi, K., Hashiya, F., Tomoike, F., Nakamoto, K., Kimura, Y., Shimizu, Y., & Abe, H. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202007111 · Cited by 57
Lipid-Nucleic Acid Complexes: Physicochemical Aspects and Prospects for Cancer Treatment
Gaspar, R., Coelho, F., & Silva, B. F. B. (2020) · Molecules · doi:10.3390/molecules25215006 · Cited by 59
RNA cancer nanomedicine: nanotechnology-mediated RNA therapy
Ferdows, B. E., Patel, D. N., Chen, W., Huang, X., Kong, N., & Tao, W. (2022) · Nanoscale · doi:10.1039/d1nr06991h · Cited by 59
Ndeupen, S., Qin, Z., Jacobsen, S., Estanbouli, H., Bouteau, A., & Igyártó, B. Z. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.04.430128 · Cited by 57
Messenger RNA-Based Vaccines Against Infectious Diseases
Alameh, M.-G., Weissman, D., & Pardi, N. (2020) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2020_202 · Cited by 96
Self-citationPrinciples and Challenges in anti-COVID-19 Vaccine Development
Strizova, Z. O., Smetanová, J., Bartůňková, J., & Milota, T. (2021) · International Archives of Allergy and Immunology · doi:10.1159/000514225 · Cited by 58
COVID-19: Insights into Potential Vaccines
Loo, K.-Y., Letchumanan, V., Ser, H., Teoh, S. L., Law, J. W., Tan, L. T., Mutalib, N. A., Chan, K., & Lee, L. (2021) · Microorganisms · doi:10.3390/microorganisms9030605 · Cited by 59
van Dülmen, M., Muthmann, N., & Rentmeister, A. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202100352 · Cited by 56
Nano-immunotherapy for each stage of cancer cellular immunity: which, why, and what?
Zuo, S., Song, J., Zhang, J., He, Z., Sun, B., & Sun, J. (2021) · Theranostics · doi:10.7150/thno.59953 · Cited by 56
Nanotechnology against COVID-19: Immunization, diagnostic and therapeutic studies
Hasanzadeh, A., Alamdaran, M., Ahmadi, S., Nourizadeh, H., Bagherzadeh, M. A., Jahromi, M. A. M., Simon, P. D., Karimi, M., & Hamblin, M. R. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.06.036 · Cited by 59
Nanotechnologies in Delivery of DNA and mRNA Vaccines to the Nasal and Pulmonary Mucosa
Tang, J., Cai, L., Xu, C., Sun, S., Liu, Y., Rosenecker, J., & Guan, S. (2022) · Nanomaterials · doi:10.3390/nano12020226 · Cited by 54
Jia, F., Huang, W., Yin, Y., Jiang, Y., Yang, Q., Huang, H., Nie, G., & Wang, H. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202204636 · Cited by 56
Mishra, G., Prajapat, V., & Nayak, D. (2023) · Immunology · doi:10.1111/imm.13695 · Cited by 63
Visualizing lipid nanoparticle trafficking for mRNA vaccine delivery in non-human primates
Buckley, M., Araínga, M., Maiorino, L., Pires, I. S., Kim, B., Michaels, K. K., Dye, J., Qureshi, K., Zhang, Y. J., Mak, H. H., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.008 · Cited by 59
A Review on the Stability Challenges of Advanced Biologic Therapeutics
Sarvepalli, S., Pasika, S. R., Verma, V., Thumma, A., Bolla, S., Nukala, P. K., Butreddy, A., & Bolla, P. K. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050550 · Cited by 63
Nelson, C. S., Herold, B. C., & Permar, S. R. (2018) · npj Vaccines · doi:10.1038/s41541-018-0074-4 · Cited by 57
Lipid-Based Vectors for Therapeutic mRNA-Based Anti-Cancer Vaccines
Guevara, M. L., Persano, S., & Persano, F. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190619150221 · Cited by 57
Nucleic Acid-Based Technologies Targeting Coronaviruses
Le, T. K., Paris, C., Khan, K. S., Robson, F., Ng, W., & Rocchi, P. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.11.010 · Cited by 57
COVID-19 vaccine platforms: Delivering on a promise?
Verdecia, M. A., Kokai‐Kun, J. F., Kibbey, M., Acharya, S., Venema, J., & Atouf, F. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1911204 · Cited by 57
COVID-19 Vaccination in Pregnancy and Lactation: Current Research and Gaps in Understanding
Shook, L. L., Fallah, P. N., Silberman, J. N., & Edlow, A. G. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.735394 · Cited by 59
Behl, A., Nair, A., Mohagaonkar, S., Yadav, P., Gambhir, K., Tyagi, N., Sharma, R. K., Butola, B. S., & Sharma, N. (2022) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2022.105217 · Cited by 58
Advanced Biomaterials for Cell‐Specific Modulation and Restore of Cancer Immunotherapy
Ruan, S., Huang, Y., He, M., & Gao, H. (2022) · Advanced Science · doi:10.1002/advs.202200027 · Cited by 54
Self-amplifying mRNA vaccines: Mode of action, design, development and optimization
Pourseif, M. M., Masoudi‐Sobhanzadeh, Y., Azari, E., Parvizpour, S., Barar, J., Ansari, R. A., & Omidi, Y. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103341 · Cited by 57
Branched hydrophobic tails in lipid nanoparticles enhance mRNA delivery for cancer immunotherapy
Yan, Y., Liu, X., Wang, L., Wu, C., Shuai, Q., Zhang, Y., & Liu, S. (2023) · Biomaterials · doi:10.1016/j.biomaterials.2023.122279 · Cited by 56
Lu, J., Atochina‐Vasserman, E. N., Maurya, D. S., Sahoo, D., Ona, N. A., Reagan, E. K., Ni, H., Weissman, D., & Percec, V. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c07337 · Cited by 55
Self-citationCurrent Progress of Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Vaccine Development
Kim, D.-K., Lai, C., Cha, I., & Jung, J. U. (2024) · Viruses · doi:10.3390/v16010128 · Cited by 59
Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion
Mitra, A., Kumar, A., Amdare, N. P., & Pathak, R. (2024) · Biology · doi:10.3390/biology13050307 · Cited by 61
Hamilton, A. G., Swingle, K. L., Thatte, A. S., Mukalel, A. J., Safford, H. C., Billingsley, M. M., El-Mayta, R. D., Han, X., Nachod, B. E., Joseph, R. A., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c01171 · Cited by 65
Immunological Analysis of a CCHFV mRNA Vaccine Candidate in Mouse Models
Farzani, T. A., Földes, K., Ergünay, K., Gürdal, H., Baştuğ, A., & Özkul, A. (2019) · Vaccines · doi:10.3390/vaccines7030115 · Cited by 55
Tanaka, H., Sakurai, Y., Anindita, J., & Akita, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.001 · Cited by 56
Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence
Zhou, X., Qu, M., Tebon, P. J., Jiang, X., Wang, C., Xue, Y., Zhu, J., Zhang, S., Öklü, R., Sengupta, S., et al. (2020) · Advanced Science · doi:10.1002/advs.202001447 · Cited by 55
Vaccination with Messenger RNA: A Promising Alternative to DNA Vaccination
Tombácz, I., Weissman, D., & Pardi, N. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0872-2_2 · Cited by 55
Self-citationGene- and Species-Specific Hox mRNA Translation by Ribosome Expansion Segments
Leppek, K., Fujii, K., Quade, N., Susanto, T. T., Boehringer, D., Lenarčič, T., Xue, S., Genuth, N. R., Ban, N., & Barna, M. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.10.023 · Cited by 56
Establishing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens
Poveda, C., Biter, A. B., Bottazzi, M. E., & Strych, U. (2019) · Vaccines · doi:10.3390/vaccines7040131 · Cited by 54
Willis, E., Pardi, N., Parkhouse, K., Mui, B. L., Tam, Y. K., Weissman, D., & Hensley, S. E. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aav5701 · Cited by 54
Self-citationAdvances in Engineering Cells for Cancer Immunotherapy
Xu, X., Li, T., Shen, S., Wang, J., Abdou, P., Gu, Z., & Mo, R. (2019) · Theranostics · doi:10.7150/thno.38583 · Cited by 53
Perspectives in Peptide-Based Vaccination Strategies for Syndrome Coronavirus 2 Pandemic
Natale, C. D., Manna, S. L., Benedictis, I. D., Brandi, P., & Marasco, D. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.578382 · Cited by 54
Metadata
- Authors
- Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D.
- Affiliations
- University of Pennsylvania (US)
- Duke University (US)
- Corresponding author
- Weissman, Drew
- Venue
- Nature Reviews Drug Discovery
- Published
- 2018-01-12
- Volume
- 17
- Issue
- 4
- Pages
- 261-279
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC5906799
- OpenAlex
- W2782708334
- Cited by
- 4,667
- References
- 218
- Citations by year
- 2026: 640 · 2025: 683 · 2024: 630 · 2023: 662 · 2022: 801 · 2021: 808 · 2020: 303 · 2019: 90 · 2018: 49
- FWCI
- 30.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bill and Melinda Gates Foundation (OPP1066832, OPP1033102)
- National Institutes of Health (AI084860, AI-100645)
- Defense Advanced Research Projects Agency (HR0011‐17‐2‐0069)
- Advanced Research Projects Agency
- National Institute of Allergy and Infectious Diseases (AI-100645, UM1AI100645, R01-AI084860, R01AI050484, R01AI124429, AI124429, U01AI067854, R01AI090788)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- mRNA vaccines, mRNA stability, mRNA delivery, vaccine platforms, cancer vaccines, infectious disease vaccines, vaccine development
- MeSH terms
- Vaccinology, Animals, Humans, Neoplasms, RNA, Messenger, Vaccines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
